Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease

Cleve Clin J Med. 1995 Sep-Oct;62(5):317-23. doi: 10.3949/ccjm.62.5.317.

Abstract

Although sulfasalazine, a 5-aminosalicylic acid (5-ASA) agent, is still the anti-inflammatory agent of choice for ulcerative colitis and Crohn's disease, newer formulations, which release drug to specific regions of the colon for maximal efficacy, also can be appropriate first-line agents. This article reviews recent clinical studies of therapy with older and newer 5-ASA formulations.

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Aminosalicylic Acids / therapeutic use*
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Azo Compounds / therapeutic use
  • Delayed-Action Preparations / therapeutic use
  • Humans
  • Hydrogen-Ion Concentration
  • Inflammatory Bowel Diseases / drug therapy*
  • Mesalamine

Substances

  • Aminosalicylic Acids
  • Anti-Inflammatory Agents, Non-Steroidal
  • Azo Compounds
  • Delayed-Action Preparations
  • Mesalamine